期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺对人类非霍奇金淋巴瘤Raji细胞血管内皮生长因子的影响 被引量：2

The study of thalidomide affecting VEGF of non-Hodgkin lymphoma Raji cells
原文传递
导出
摘要 目的 探讨沙利度胺体外对人类非霍奇金淋巴瘤(NHL)Raji细胞血管内皮生长因子(VEGF)的影响及其作用机制.方法 采用MTT法检测沙利度胺对人类NHL Raji细胞是否有抑制作用,采用ELISA法检测沙利度胺作用前后Raji细胞上清液中VEGF含量的变化.结果 MTT法示沙利度胺体外对人类NHL Raji细胞无直接的抑制作用(P＞0.05).ELISA法示10、25、50 mg/L的沙利度胺组对Raji细胞分泌VEGF均有明显抑制作用(P＜0.05).5 mg/L沙利度胺组及0.1%DMSO对照组对Raji细胞分泌VEGF无明显抑制作用(P＞0.05).沙利度胺对Raji细胞分泌VEGF的抑制作用随着浓度和时间的递增而增加.结论沙利度胺能够抑制人类NHL Raji细胞分泌VEGF并且存在时间和浓度依赖性.沙利度胺体外对Raji细胞并无明显直接的抗增生效应与细胞毒活性.
作者 陈贝贝 钟美佐 余兴 曾佳 黄进
机构地区 中南大学湘雅医院肿瘤科
出处 《白血病．淋巴瘤》 CAS 2008年第1期-,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 非霍奇金 细胞系 肿瘤 药物筛选试验 抗肿瘤 血管内皮生长因子
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Komorowski J,Jerezynska H,Siejka A. Effect of thalidomide affecting VEGF secretion,cell migration,adhesion and capillary tube formation of human endothelial EA.hy 926 cells[J].Life Sciences,2006,(22):2558-2563.doi:10.1016/j.lfs.2005.10.016.
  • 2叶进,刘复强,吴轶苹.VEGF及其受体在恶性血液细胞系HL-60及Raji的表达[J].中国实验血液学杂志,2003,11(4):376-380. 被引量：3
  • 3D'Amato RJ,Loughnan MS,Flynn E. Thalidomide is an inhibitor of angiogenesis[J].Proceedings of the National Academy of Sciences(USA),1991,(09):4082-4085.
  • 4Verheul HM,Panigraphy D,Yuan J. Combination oral antiangiogenic therapy with thalidomide and sulindae inhibits tumour growth in rabbits[J].British Journal of Cancer,1999,(01):114-118.doi:10.1038/sj.bjc.6690020.
  • 5Kaufmann H,Raderer M,Wohrer S. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma[J].Blood,2004,(08):2269-2271.doi:10.1182/blood-2004-03-1091.
  • 6Damaj G,Lefrere F,Delarue R. Thalidomide therapy induces response in relapsed mantle cell lymphoma[J].Leukemia:Official Journal of the Leukemia Society of America Leukemia Research Fund U K,2003,(09):1914-1915.
  • 7黄慧强,卜庆,黄欣,周中梅.沙利度胺单药治疗三例耐药滤泡型淋巴瘤患者[J].中华血液学杂志,2006,27(10):704-705. 被引量：5
  • 8Podar K,Tai YT,Davies FE. Vascular endothelial growth factor triggers signaling cascades mediating Multiple Myleoma cells growth and migration[J].Blood,2001,(02):428-435.doi:10.1182/blood.V98.2.428.
  • 9Kim JK,Li B,Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo[J].Nature,1993,(6423):841-844.doi:10.1038/362841a0.
  • 10Ho CL,Sheu LF,Li CY. Immunohistochemical expression of basic fibroblast growth factor,vascular endothelial growth factor,and their receptors in stage Ⅳ non-Hodgkin lymphoma[J].Applied Immunohistochemistry & Molecular Morphology,2002,(04):316-321.doi:10.1097/00022744-200212000-00005.

二级参考文献24

  • 1Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med, 1971; 285:1182- 1186.
  • 2Cohen T, Nahari D, Cerem LW, et al. lnterleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem,1996; 271:736 - 741.
  • 3Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med,1991; 324:1-8.
  • 4Ohta Y, Endo Y, Tanaka, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res, 1996; 2:1411- 1416.
  • 5Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res, 1997; 3:2507- 2511.
  • 6Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol,1993; 143:401 - 409.
  • 7Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lympboblasticleukemia. Am J Pathol, 1997; 150:815- 821.
  • 8Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997; 89:1870 - 1875.
  • 9Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999; 94:3717- 3721.
  • 10Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 1997; 90:3167- 3172.

共引文献6

同被引文献9

引证文献2

二级引证文献7

白血病．淋巴瘤
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部